Adenine Phosphoribosyltransferase Deficiency

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Catherine Yang	+ 519 word(s)	519	2020-12-15 07:14:53	\|
2	format correct	Catherine Yang	Meta information modification	519	2020-12-24 03:55:21	\|

This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/condition/adenine-phosphoribosyltransferase-deficiency

Adenine phosphoribosyltransferase (APRT) deficiency is an inherited condition that affects the kidneys and urinary tract. The most common feature of this condition is recurrent kidney stones; urinary tract stones are also a frequent symptom. Kidney and urinary tract stones can create blockages in the urinary tract, causing pain during urination and difficulty releasing urine.

genetic conditions

1. Introduction

Affected individuals can develop features of this condition anytime from infancy to late adulthood. When the condition appears in infancy, the first sign is usually the presence of tiny grains of reddish-brown material in the baby's diaper caused by the passing of stones. Later, recurrent kidney and urinary tract stones can lead to problems with kidney function beginning as early as mid- to late childhood. Approximately half of individuals with APRT deficiency first experience signs and symptoms of the condition in adulthood. The first features in affected adults are usually kidney stones and related urinary problems. Other signs and symptoms of APRT deficiency caused by kidney and urinary tract stones include fever, urinary tract infection, blood in the urine (hematuria), abdominal cramps, nausea, and vomiting.

Without treatment, kidney function can decline, which may lead to end-stage renal disease (ESRD). ESRD is a life-threatening failure of kidney function that occurs when the kidneys are no longer able to filter fluids and waste products from the body effectively.

The features of this condition and their severity vary greatly among affected individuals, even among members of the same family. It is estimated that 15 to 20 percent of people with APRT deficiency do not have any signs or symptoms of the condition.

2. Frequency

APRT deficiency is estimated to affect 1 in 27,000 people in Japan. The condition is rarer in Europe, where it is thought to affect 1 in 50,000 to 100,000 people. The prevalence of APRT deficiency outside these populations is unknown.

3. Causes

Mutations in the APRT gene cause APRT deficiency. This gene provides instructions for making APRT, an enzyme that helps to convert a DNA building block (nucleotide) called adenine to a molecule called adenosine monophosphate (AMP). This conversion occurs when AMP is needed as a source of energy for cells.

APRT gene mutations lead to the production of an abnormal APRT enzyme with reduced function or prevent the production of any enzyme. A lack of functional enzyme impairs the conversion of adenine to AMP. As a result, adenine is converted to another molecule called 2,8-dihydroxyadenine (2,8-DHA). 2,8-DHA crystallizes in urine, forming stones in the kidneys and urinary tract. 2,8-DHA crystals are brownish in color, which explains why affected infants frequently have dark urine stains in their diapers. 2,8-DHA is toxic to kidneys, which may explain the possible decline in kidney function and the progression to ESRD.

4. Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

5. Other Names for This Condition

2,8-dihydroxyadenine urolithiasis
2,8-dihydroxyadeninuria
APRT deficiency
DHA crystalline nephropathy

References

Bollée G, Dollinger C, Boutaud L, Guillemot D, Bensman A, Harambat J, DeteixP, Daudon M, Knebelmann B, Ceballos-Picot I. Phenotype and genotypecharacterization of adenine phosphoribosyltransferase deficiency. J Am SocNephrol. 2010 Apr;21(4):679-88. doi: 10.1681/ASN.2009080808.
Bollée G, Harambat J, Bensman A, Knebelmann B, Daudon M, Ceballos-Picot I.Adenine phosphoribosyltransferase deficiency. Clin J Am Soc Nephrol. 2012Sep;7(9):1521-7.
Edvardsson VO, Sahota A, Palsson R. Adenine PhosphoribosyltransferaseDeficiency. 2012 Aug 30 [updated 2019 Sep 26]. In: Adam MP, Ardinger HH, PagonRA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Availablefrom http://www.ncbi.nlm.nih.gov/books/NBK100238/
Harambat J, Bollée G, Daudon M, Ceballos-Picot I, Bensman A; APRT Study Group.Adenine phosphoribosyltransferase deficiency in children. Pediatr Nephrol. 2012Apr;27(4):571-9. doi: 10.1007/s00467-011-2037-0.

©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Genetics & Heredity

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Catherine Yang

View Times: 327

Entry Collection: MedlinePlus

Update Date: 24 Dec 2020

Table of Contents

Video Upload Options

Confirm

1. Introduction

2. Frequency

3. Causes

4. Inheritance

5. Other Names for This Condition

References

Video Upload Options

Confirm

1. Introduction

2. Frequency

3. Causes

3.1. The gene associated with Adenine phosphoribosyltransferase deficiency

4. Inheritance

5. Other Names for This Condition

References